Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1994 Jun;112(2):453–460. doi: 10.1111/j.1476-5381.1994.tb13094.x

Mediation by bradykinin of rat paw oedema induced by collagenase from Clostridium histolyticum.

F J Legat 1, T Griesbacher 1, F Lembeck 1
PMCID: PMC1910340  PMID: 7915609

Abstract

1. Collagenases are thought to play a major role in the pathology of gas gangrene caused by Clostridium histolyticum, because they can destroy the connective tissue barriers. We investigated possible mediators involved in the oedema formation and plasma protein extravasation which follow the injection of a collagenase (EC 3.4.24.3) from Clostridium histolyticum into one hind paw of anaesthetized rats. 2. The magnitude of the oedema following a subplantar injection was dependent on the dose of collagenase (30, 100 and 300 micrograms) injected. It reached its maximum within 30 min and remained unchanged for at least 5 h. Plasma protein extravasation into the paw was most pronounced within 20 min of the injection. Heat-inactivated collagenase was ineffective. 3. The B2 bradykinin (BK) antagonist icatibant (D-Arg-[Hyp3-Thi5-D-Tic7- Oic8] bradykinin, formerly named Hoe-140) reduced oedema formation in a dose-dependent manner with a maximal reduction of around 65% at a dose of 100 nmol kg-1 (s.c.). A significant effect could already be observed at a dose of 10 nmol kg-1. The duration of the effect of icatibant (100 nmol kg-1) was found to be at least 3 h. These results demonstrate the high potency and long duration of action of icatibant. Pretreatment of rats with the bradykinin B1 antagonist, des-Arg9-[Leu8]-BK did not affect collagenase-induced paw oedema. Thus, the observed collagenase-induced effects are mainly mediated by BK through activation of B2 receptors.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
454

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cohen S. R., Abbott F. V., Melzack R. Unilateral analgesia produced by intraventricular morphine. Brain Res. 1984 Jun 15;303(2):277–287. doi: 10.1016/0006-8993(84)91214-9. [DOI] [PubMed] [Google Scholar]
  2. Constantine J. W., Lebel W. S., Woody H. A. Inhibition of tachykinin-induced hypotension in dogs by CP-96,345, a selective blocker of NK-1 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1991 Oct;344(4):471–477. doi: 10.1007/BF00172588. [DOI] [PubMed] [Google Scholar]
  3. Damas J., Remacle-Volon G. Influence of a long-acting bradykinin antagonist, Hoe 140, on some acute inflammatory reactions in the rat. Eur J Pharmacol. 1992 Jan 28;211(1):81–86. doi: 10.1016/0014-2999(92)90266-7. [DOI] [PubMed] [Google Scholar]
  4. Donnerer J., Stark U., Tritthart H. A., Lembeck F. CP-96,345, a non-peptide antagonist of substance P. III. Cardiovascular effects in mammals unrelated to actions on substance P receptors. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):328–332. doi: 10.1007/BF00173547. [DOI] [PubMed] [Google Scholar]
  5. Esplugues J. V., Whittle B. J., Moncada S. Local opioid-sensitive afferent sensory neurones in the modulation of gastric damage induced by Paf. Br J Pharmacol. 1989 Jun;97(2):579–585. doi: 10.1111/j.1476-5381.1989.tb11988.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gamse R., Holzer P., Lembeck F. Decrease of substance P in primary afferent neurones and impairment of neurogenic plasma extravasation by capsaicin. Br J Pharmacol. 1980 Feb;68(2):207–213. doi: 10.1111/j.1476-5381.1980.tb10409.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gamse R., Leeman S. E., Holzer P., Lembeck F. Differential effects of capsaicin on the content of somatostatin, substance P, and neurotensin in the nervous system of the rat. Naunyn Schmiedebergs Arch Pharmacol. 1981 Sep;317(2):140–148. doi: 10.1007/BF00500070. [DOI] [PubMed] [Google Scholar]
  8. Geppetti P. Sensory neuropeptide release by bradykinin: mechanisms and pathophysiological implications. Regul Pept. 1993 Aug 13;47(1):1–23. doi: 10.1016/0167-0115(93)90268-d. [DOI] [PubMed] [Google Scholar]
  9. Griesbacher T., Donnerer J., Legat F. J., Lembeck F. CP-96,345, a non-peptide antagonist of substance P: II. Actions on substance P-induced hypotension and bronchoconstriction, and on depressor reflexes in mammals. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):323–327. doi: 10.1007/BF00173546. [DOI] [PubMed] [Google Scholar]
  10. Han S., Blumenfeld O. O., Seifter S. Specific identification of collagens and their fragments by clostridial and anti-collagenase antibody. Anal Biochem. 1992 Mar;201(2):336–342. doi: 10.1016/0003-2697(92)90348-b. [DOI] [PubMed] [Google Scholar]
  11. Hatheway C. L. Toxigenic clostridia. Clin Microbiol Rev. 1990 Jan;3(1):66–98. doi: 10.1128/cmr.3.1.66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hock F. J., Wirth K., Albus U., Linz W., Gerhards H. J., Wiemer G., Henke S., Breipohl G., König W., Knolle J. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol. 1991 Mar;102(3):769–773. doi: 10.1111/j.1476-5381.1991.tb12248.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Just D., Urbanitz D., Habermann E. Pharmakologische Charakterisierung der vasculären Schrankenfunktion gegenüber Erythrocyten und Albumin. Naunyn Schmiedebergs Arch Pharmakol. 1970;267(5):399–420. [PubMed] [Google Scholar]
  14. Lembeck F., Donnerer J., Tsuchiya M., Nagahisa A. The non-peptide tachykinin antagonist, CP-96,345, is a potent inhibitor of neurogenic inflammation. Br J Pharmacol. 1992 Mar;105(3):527–530. doi: 10.1111/j.1476-5381.1992.tb09013.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lembeck F., Griesbacher T., Eckhardt M., Henke S., Breipohl G., Knolle J. New, long-acting, potent bradykinin antagonists. Br J Pharmacol. 1991 Feb;102(2):297–304. doi: 10.1111/j.1476-5381.1991.tb12169.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lembeck F., Griesbacher T., Legat F. J. Lack of significant unspecific effects of HOE 140 and other novel bradykinin antagonists in vitro and in vivo. Agents Actions Suppl. 1992;38(Pt 2):414–422. [PubMed] [Google Scholar]
  17. McLean S., Ganong A. H., Seeger T. F., Bryce D. K., Pratt K. G., Reynolds L. S., Siok C. J., Lowe J. A., 3rd, Heym J. Activity and distribution of binding sites in brain of a nonpeptide substance P (NK1) receptor antagonist. Science. 1991 Jan 25;251(4992):437–439. doi: 10.1126/science.1703324. [DOI] [PubMed] [Google Scholar]
  18. Parker M. T. Postoperative clostridial infections in Britain. Br Med J. 1969 Sep 20;3(5672):671–676. doi: 10.1136/bmj.3.5672.671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Rhaleb N. E., Rouissi N., Jukic D., Regoli D., Henke S., Breipohl G., Knolle J. Pharmacological characterization of a new highly potent B2 receptor antagonist (HOE 140: D-Arg-[Hyp3,Thi5,D-Tic7,Qic8]bradykinin). Eur J Pharmacol. 1992 Jan 14;210(2):115–120. doi: 10.1016/0014-2999(92)90661-m. [DOI] [PubMed] [Google Scholar]
  20. Snider R. M., Constantine J. W., Lowe J. A., 3rd, Longo K. P., Lebel W. S., Woody H. A., Drozda S. E., Desai M. C., Vinick F. J., Spencer R. W. A potent nonpeptide antagonist of the substance P (NK1) receptor. Science. 1991 Jan 25;251(4992):435–437. doi: 10.1126/science.1703323. [DOI] [PubMed] [Google Scholar]
  21. Tomkinson A., Karlsson J. A., Raeburn D. Comparison of the effects of selective inhibitors of phosphodiesterase types III and IV in airway smooth muscle with differing beta-adrenoceptor subtypes. Br J Pharmacol. 1993 Jan;108(1):57–61. doi: 10.1111/j.1476-5381.1993.tb13439.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Vargaftig B. B., Lefort J., Giroux E. L. Haemorrhagic and inflammatory properties of collagenase from C. histolyticum. Agents Actions. 1976 Sep;6(5):627–635. doi: 10.1007/BF01971582. [DOI] [PubMed] [Google Scholar]
  23. Wirth K., Hock F. J., Albus U., Linz W., Alpermann H. G., Anagnostopoulos H., Henk S., Breipohl G., König W., Knolle J. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol. 1991 Mar;102(3):774–777. doi: 10.1111/j.1476-5381.1991.tb12249.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES